Atyr Pharma Inc (NASDAQ: ATYR) started the day on Thursday, with a price decrease of -4.62% at $3.10, before settling in for the price of $3.25 at the close. Taking a more long-term approach, ATYR posted a 52-week range of $1.08-$3.68.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 436.18%. Meanwhile, its Annual Earning per share during the time was 43.36%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 5.17%. This publicly-traded company’s shares outstanding now amounts to $75.80 million, simultaneously with a float of $73.81 million. The organization now has a market capitalization sitting at $234.97 million. At the time of writing, stock’s 50-day Moving Average stood at $2.32, while the 200-day Moving Average is $1.92.
Atyr Pharma Inc (ATYR) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Atyr Pharma Inc’s current insider ownership accounts for 2.61%, in contrast to 70.11% institutional ownership. According to the most recent insider trade that took place on Jul 24 ’24, this organization’s Director bought 52,300 shares at the rate of 1.93, making the entire transaction reach 101,038 in total value, affecting insider ownership by 413,023. Preceding that transaction, on Jul 22 ’24, Company’s Director bought 41,052 for 1.74, making the whole transaction’s value amount to 71,500. This particular insider is now the holder of 354,075 in total.
Atyr Pharma Inc (ATYR) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.23 per share during the current fiscal year.
Atyr Pharma Inc’s EPS increase for this current 12-month fiscal period is 5.17% and is forecasted to reach -0.77 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 13.00% through the next 5 years, which can be compared against the 43.36% growth it accomplished over the previous five years trading on the market.
Atyr Pharma Inc (NASDAQ: ATYR) Trading Performance Indicators
Let’s observe the current performance indicators for Atyr Pharma Inc (ATYR). It’s Quick Ratio in the last reported quarter now stands at 7.63. The Stock has managed to achieve an average true range (ATR) of 0.23. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 398.26.
In the same vein, ATYR’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.91, a figure that is expected to reach -0.23 in the next quarter, and analysts are predicting that it will be -0.77 at the market close of one year from today.
Technical Analysis of Atyr Pharma Inc (ATYR)
If we take a close look at the recent performances of Atyr Pharma Inc (NASDAQ: ATYR), its last 5-days Average volume was 0.64 million that shows progress from its year to date volume of 0.56 million. During the previous 9 days, stock’s Stochastic %D was recorded 35.83% While, its Average True Range was 0.24.
Raw Stochastic average of Atyr Pharma Inc (ATYR) in the period of the previous 100 days is set at 74.34%, which indicates a major rise in contrast to 27.50% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 55.56% that was lower than 74.55% volatility it exhibited in the past 100-days period.
